Wet age-related macular degeneration Trials in Springfield, United States
Conditions / Wet age-related macular degeneration / Springfield, United States
Research into Wet age-related macular degeneration spans multiple therapeutic approaches and trial phases.
10 total trials for this combination
Trials
| NCT ID | Title | Status | Phase |
|---|---|---|---|
| NCT04480463 | A Study to Comparing SCD411 and Eylea® in Subjects With Wet Age-related Macular Degeneration (AMD) | COMPLETED | PHASE3 |
| NCT04747197 | First in Human Study to Evaluate the Safety and Tolerability of EYP-1901 in Patients With Wet Age Related Macular Degeneration (wAMD) | COMPLETED | PHASE1 |
| NCT04704921 | Pivotal 1 Study of ABBV-RGX-314 (Also Known as RGX-314) Gene Therapy Administered Via Subretinal Delivery One Time in Participants With nAMD | ACTIVE_NOT_RECRUITING | — |
| NCT06683742 | A 2-year Study of EYP-1901 in Subjects With Wet Age Related Macular Degeneration (wAMD) (LUCIA) Primary Efficacy Will be Determined at Week 56 | ACTIVE_NOT_RECRUITING | PHASE3 |
| NCT00138632 | Safety and Efficacy of Oral PTK787 in Patients With Subfoveal Choroidal Neovascularization Secondary to Age-Related Macular Degeneration (AMD) | COMPLETED | PHASE1/PHASE2 |
| NCT06556368 | A Study to Evaluate the Efficacy and Safety of Tarcocimab Tedromer and Tabirafusp Tedromer Compared to Aflibercept in Participants With Neovascular (Wet) Age-related Macular Degeneration (wAMD) - DAYBREAK | ACTIVE_NOT_RECRUITING | — |
| NCT06668064 | A 2-year Study of EYP-1901 in Subjects With Wet Age Related Macular Degeneration (wAMD) (LUGANO) Primary Efficacy Will be Determined at Week 56 | ACTIVE_NOT_RECRUITING | PHASE3 |
| NCT05381948 | Study of EYP-1901 in Subjects With Wet Age Related Macular Degeneration (wAMD) | COMPLETED | PHASE2 |
| NCT04964089 | A Study to Evaluate the Efficacy and Safety of Intravitreal KSI-301 Compared With Intravitreal Aflibercept in Participants With Neovascular (Wet) Age-related Macular Degeneration (wAMD) | COMPLETED | PHASE3 |
| NCT05407636 | Pivotal 2 Study of RGX-314 Gene Therapy in Participants With nAMD | RECRUITING | PHASE3 |